Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00174421 | Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height | PHASE3 | COMPLETED | 36 | — | — | Apr 1, 2001 | Aug 1, 2005 | May 3, 2007 | - | — |
| Name | Type | Description |
|---|---|---|
| Treatment with Genotropin in different dosages | DRUG | - |
Inclusion Criteria: * Participation in the 90-080 study Exclusion Criteria: * Any severe, acute or chronic disease * Any other identifiable reason for short stature
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Somapacitan, Norditropin FlexPro |
| Ascendis Pharma A/S | ASND | 1 | PHASE3 | Lonapegsomatropin, Somatropin Pen Injector |
| Harvard Bioscience, Inc. | HBIO | 1 | NA | Undisclosed |